PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients

CompletedOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

July 1, 2021

Study Completion Date

May 31, 2022

Conditions
Prostate Cancer
Interventions
DIAGNOSTIC_TEST

Invitae multi-cancer gene panel

Invitae's multi-cancer panel tests for 84 genes associated with hereditary cancer risk.

Trial Locations (19)

10016

Perlmutter Cancer Center, NYU Langone Health, New York, New York

13210

Associated Medical Professionals, Syracuse

19004

MidLantic Urology, Bala-Cynwyd

29572

Carolina Urologic Research Center, Myrtle Beach

30720

North Georgia Urology, Dalton

33606

Florida Urology Partners, Tampa

TGH Cancer Institute, Tampa

33710

Advanced Urology Institute, St. Petersburg

37211

Urology Associates, P.C., Nashville

60415

Associated Urological Specialists, Chicago Ridge

76017

Urology Partners, Arlington

77002

Urosurgery Houston, Houston

78759

Urology Austin, Austin

80228

Colorado Urology, Lakewood

92123

Genesis Healthcare Partners, San Diego

94103

Invitae, San Francisco

94158

Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco

Volunteer Faculty, University of California San Francisco, San Francisco

08690

University Urology Associates of New Jersey, Hamilton

Sponsors
All Listed Sponsors
lead

Invitae Corporation

INDUSTRY

NCT05447637 - PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients | Biotech Hunter | Biotech Hunter